HR and breast carcinoma: Similarly, gBRCA-positive patients participating in the MULAN trial (NCT04355858), a prospective, single-center, open-label, umbrella-shaped phase II clinical study for patients with HR+/HER2– endocrine-resistant advanced breast cancer, also received PARPi.